News from Nanoscope
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis Pigmentosa
- 88.9% (16/18) of MCO-010 treated patients experienced a clinically meaningful 2 or more luminance level improvement in vision-guided mobility or object recognition
- Clinically meaningful visual acuity gains observed in several MCO-010 treated patients
- Favorable safety profile for MCO-010 with no serious or severe adverse events
READ COMPLETE PRESS RELEASE
Nanoscope Therapeutics is advancing gene therapy using ambient light-sensitive molecules, bringing hope for renewed sight to millions of people blinded by retinal degenerative diseases for which no cure exists.
Nanoscope is focused on proprietary ambient light-activated optogenetic therapy to restore vision in people suffering from various inherited retinal degenerative diseases including Retinitis Pigmentosa, Stargardt, and dry AMD.
Genetic retinal degenerative diseases cause vision loss as cells of the retina gradually become dysfunctional. Nanoscope’s proprietary gene therapies correct the condition by delivering light-sensitive molecules, called Multi-Characteristic Opsins (MCO), into retinal cells.
LEARN ABOUT OUR TECHNOLOGY
Our lead gene therapy product in clinical trials for retinitis pigmentosa will be the first therapy to correct the condition and is applicable for patients with complete or partial degeneration of the retina.
Pioneering a New Wave of Optogenetic Therapeutics for Vision Restoration
Nanoscope News & Events
Nanoscope Therapeutics Announces Positive Topline Results from Phase 2b RESTORE Trial of MCO-010 for the Treatment of Retinitis PigmentosaMarch 30, 2023
Nanoscope Therapeutics Appoints Industry Veteran Vicente Anido Jr., Ph.D., as a Strategic AdvisorMarch 20, 2023
Nanoscope Therapeutics Announces World Health Organization Selection of "Sonpiretigene Isteparvovec" as International Nonproprietary Name for MCO-010February 28, 2023
Nanoscope Therapeutics CEO Sulagna Bhattacharya Joins BIO Health Section Governing BoardFebruary 13, 2023
Nanoscope Therapeutics to Present at the BIO CEO & Investor ConferenceFebruary 2, 2023
Nanoscope Therapeutics Receives Fast Track Designation by the FDA for MCO-010 for the Treatment of Stargardt DiseaseJanuary 30, 2023
Nanoscope Therapeutics Announces Presentations at the Optogenetics and Optical Manipulation ConferenceJanuary 23, 2023
Nanoscope Therapeutics to Present at the Next Generation Ophthalmic Drug Delivery SummitJanuary 19, 2023